## ICMJE DISCLOSURE FORM

Date:	7/27/2021
Your Name:	Heiman Wertheim
Manuscript Title:	Carbapenems: inzetten als het moet, vermijden als het kan
Manuscript Number (if known):	BTW D7047R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None None	Click the tab key to add additional rows.		
		Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None  Wellcome Trust Pfizer MSD ZonMW	ABACUS project Unrestricted science grant Grant for developing teaching materials Proswap studie		
3	Royalties or licenses	None     Non			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None  Destiny Pharma	Consulting for new S aureus nasal ointment
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AIOS cursus infectiepreventie ISAC	Develop antibiotic treatment guideline
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	□ None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	For UMCU trial	BCG vaccination to prevent COVID-19
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None  President  Member  Member	NVMM International Society of Antimicrobial Chemotherapy Beraadsgroep Gezondheidsraad

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	□ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None		
13	Other financial or non-financial interests	□ None		
Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			